TRYNGOLZA™ (olezarsen) has received U.S. approval as the first treatment for adults with familial chylomicronemia syndrome, used alongside dietary changes.
Adicet Bio has reported the dosing of the initial patient in a Phase 1 clinical trial for ADI-270 targeting metastatic/advanced clear cell renal cell carcinoma.
Neurocrine Biosciences has received FDA approval for CRENESSITY™ (crinecerfont), the first of its kind therapy for both children and adults suffering from classic congenital adrenal hyperplasia.